Androgen and ar contribute to breast cancer development and metastasis: an insight of mechanisms

ABSTRACT The role of androgen and androgen receptor (AR) in breast carcinogenesis has long been a disputed issue. This report provides a mechanistic insight into how androgen and AR

contributes to invasion and metastasis of breast cancer. We find that dihydrotestosterone (DHT) is able to induce the epithelial-to-mesenchymal transition in breast cancer cells in an

AR-dependent/estrogen receptor-independent manner. This process is dependent on the demethylation activity of lysine-specific demethylase 1A (LSD1) by epigenetically regulating the target

genes E-cadherin and vimentin. _In vivo_, DHT promotes metastasis in a nude mouse model, and AR and LSD1 are indispensable in this process. We establish that higher expression of nucleus AR

to cytoplasm AR associated with worse prognostic outcomes in breast cancer patient samples. This study maps an ‘androgen-AR/LSD1-target genes’ pathway in breast carcinogenesis, implicating

the importance of hormonal balance in women, and the potential clinical significance of serum androgen and AR in prediction of breast cancer and selection of breast cancer therapy. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 50 print issues and online access $259.00 per year only $5.18 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may

be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS ARE WE THERE YET? UNDERSTANDING ANDROGEN RECEPTOR SIGNALING IN BREAST CANCER Article Open access 25 September 2020 THE ANDROGEN RECEPTOR IS A TUMOR

SUPPRESSOR IN ESTROGEN RECEPTOR–POSITIVE BREAST CANCER Article 18 January 2021 ANDROGEN DEPRIVATION RESTORES ARHGEF2 TO PROMOTE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER Article Open

access 05 November 2022 REFERENCES * McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ . Measurement of sex steroids in murine blood and reproductive tissues by

liquid chromatography-tandem mass spectrometry. _J Steroid Biochem Mol Biol_ 2010; 121: 611–618. Article  CAS  PubMed  Google Scholar  * Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA .

Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. _Breast Cancer Res_ 2010; 12: R98. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C _et al_. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective

Investigation into Cancer and Nutrition (EPIC). _J Natl Cancer Inst_ 2005; 97: 755–765. Article  CAS  PubMed  Google Scholar  * Yu H, Shu XO, Shi R, Dai Q, Jin F, Gao YT _et al_. Plasma sex

steroid hormones and breast cancer risk in Chinese women. _Int J Cancer_ 2003; 105: 92–97. Article  CAS  PubMed  Google Scholar  * Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J,

Gunu R _et al_. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. _Endocr Relat Cancer_ 2012; 19: 137–147.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V _et al_. Sex hormone levels, breast cancer risk, and cancer receptor status

in postmenopausal women: the ORDET cohort. _Cancer Epidemiol Biomarkers Prev_ 2009; 18: 169–176. Article  CAS  PubMed  Google Scholar  * Wang B, Mi M, Wang J, Wei N, Zhang Q, Zhu J _et al_.

Does the increase of endogenous steroid hormone levels also affect breast cancer risk in Chinese women? A case-control study in Chongqing, China. _Int J Cancer_ 2009; 124: 1892–1899.

Article  CAS  PubMed  Google Scholar  * Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C _et al_. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European

prospective investigation into cancer and nutrition. _Endocr Relat Cancer_ 2005; 12: 1071–1082. Article  CAS  PubMed  Google Scholar  * Zeleniuch-Jacquotte A, Shore RE, Koenig KL,

Akhmedkhanov A, Afanasyeva Y, Kato I _et al_. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. _Br J Cancer_ 2004; 90:

153–159. Article  CAS  PubMed  PubMed Central  Google Scholar  * Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE . Endogenous estrogen, androgen, and progesterone concentrations and

breast cancer risk among postmenopausal women. _J Natl Cancer Inst_ 2004; 96: 1856–1865. Article  CAS  PubMed  Google Scholar  * Key T, Appleby P, Barnes I, Reeves G, Endogenous H, . Breast

Cancer Collaborative G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. _J Natl Cancer Inst_ 2002; 94: 606–616. Article  CAS 

PubMed  Google Scholar  * Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A _et al_. Serum testosterone levels and breast cancer recurrence. _Int J Cancer_ 2005; 113:

499–502. Article  CAS  PubMed  Google Scholar  * Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H _et al_. Evaluation of the prognostic significance of androgen

receptor expression in metastatic breast cancer. _Virchows Arch_ 2006; 449: 24–30. Article  CAS  PubMed  Google Scholar  * Agrawal AK, Jelen M, Grzebieniak Z, Zukrowski P, Rudnicki J,

Nienartowicz E . Androgen receptors as a prognostic and predictive factor in breast cancer. _Folia Histochem Cytobiol_ 2008; 46: 269–276. Article  PubMed  Google Scholar  * Gonzalez LO,

Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC _et al_. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis,

and expression of metalloproteases and their inhibitors. _BMC Cancer_ 2008; 8: 149. Article  PubMed  PubMed Central  CAS  Google Scholar  * Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman

G _et al_. Lack of expression of androgen receptor may play a critical role in transformation from _in situ_ to invasive basal subtype of high-grade ductal carcinoma of the breast. _Hum

Pathol_ 2008; 39: 386–392. Article  CAS  PubMed  Google Scholar  * Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH _et al_. Expression of androgen receptors in primary breast cancer. _Ann

Oncol_ 2010; 21: 488–492. Article  CAS  PubMed  Google Scholar  * Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ _et al_. Expression of androgen receptor in breast cancer and its

significance as a prognostic factor. _Ann Oncol_ 2011; 22: 1288–1294. Article  CAS  PubMed  Google Scholar  * Peters KM, Edwards SL, Nair SS, French JD, Bailey PJ, Salkield K _et al_.

Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. _BMC Cancer_ 2012; 12: 132. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y _et al_. Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy. _Breast Cancer_

2013; 20: 323–330. Article  Google Scholar  * Qu Q, Mao Y, Fei XC, Shen KW . The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis.

_PLoS One_ 2013; 8: e82650. Article  PubMed  PubMed Central  CAS  Google Scholar  * Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M _et al_. Androgen

receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. _J Natl Cancer Inst_ 2014; 106: djt319. Article  PubMed  CAS  Google Scholar  * Shufelt CL,

Braunstein GD . Testosterone and the breast. _Menopause Int_ 2008; 14: 117–122. Article  PubMed  Google Scholar  * McNamara KM, Nakamura Y, Miki Y, Sasano H . Phase two steroid metabolism

and its roles in breast and prostate cancer patients. _Front Endocrinol (Lausanne)_ 2013; 4: 116. Article  Google Scholar  * Chen J, Wang WQ, Lin SX . Interaction of

Androst-5-ene-3beta,17beta-diol and 5alpha-androstane-3beta,17beta-diol with estrogen and androgen receptors: a combined binding and cell study. _J Steroid Biochem Mol Biol_ 2013; 137:

316–321. Article  CAS  PubMed  Google Scholar  * Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS _et al_. Selective androgen receptor modulators (SARMs) negatively regulate

triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. _PLoS One_ 2014; 9: e103202. Article  PubMed  PubMed Central  CAS  Google Scholar  * Liu YN, Liu Y, Lee

HJ, Hsu YH, Chen JH . Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. _Mol Cell Biol_ 2008; 28: 7096–7108. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ _et al_. The growth response to androgen receptor signaling in ERalpha-negative human breast

cells is dependent on p21 and mediated by MAPK activation. _Breast Cancer Res_ 2012; 14: R27. Article  CAS  PubMed  PubMed Central  Google Scholar  * Cochrane DR, Bernales S, Jacobsen BM,

Cittelly DM, Howe EN, D'Amato NC _et al_. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. _Breast Cancer Res_ 2014; 16: R7. Article  PubMed 

PubMed Central  CAS  Google Scholar  * Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS _et al_. Amplitude modulation of androgen signaling by c-MYC. _Genes Dev_ 2013; 27: 734–748. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE _et al_. Androgen receptor exon 1 CAG repeat length and breast cancer in women before

age forty years. _J Natl Cancer Inst_ 1999; 91: 961–966. Article  CAS  PubMed  Google Scholar  * Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ _et al_. Androgen induces a

switch from cytoplasmic retention to nuclear import of the androgen receptor. _Mol Cell Biol_ 2013; 33: 4766–4778. Article  CAS  PubMed  PubMed Central  Google Scholar  * Metzger E, Wissmann

M, Yin N, Muller JM, Schneider R, Peters AH _et al_. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. _Nature_ 2005; 437: 436–439. Article 

CAS  PubMed  Google Scholar  * Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z _et al_. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor

through recruitment of lysine-specific demethylase 1. _Cancer Cell_ 2011; 20: 457–471. Article  CAS  PubMed  PubMed Central  Google Scholar  * Li Y, Wan X, Wei Y, Liu X, Lai W, Zhang L _et

al_. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion. _Oncol Rep_ 2016; 35: 3586–3592. Article  CAS  PubMed  Google Scholar  * Luo H, Shenoy

AK, Li X, Jin Y, Jin L, Cai Q _et al_. MOF acetylates the histone demethylase LSD1 to suppress epithelial-to-mesenchymal transition. _Cell Rep_ 2016; 15: 2665–2678. Article  CAS  PubMed 

Google Scholar  * Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente Z, Soliera AR, Cattelani S _et al_. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer

cell invasion. _Cancer Res_ 2013; 73: 235–245. Article  CAS  PubMed  Google Scholar  * Nam HJ, Boo K, Kim D, Han DH, Choe HK, Kim CR _et al_. Phosphorylation of LSD1 by PKCalpha is crucial

for circadian rhythmicity and phase resetting. _Mol Cell_ 2014; 53: 791–805. Article  CAS  PubMed  Google Scholar  * Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N _et al_.

Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. _Nature_ 2010; 464: 792–796. Article  CAS  PubMed  Google Scholar  * Remmele W, Hildebrand U, Hienz HA,

Klein P-J, Vierbuchen M, Behnken LJ _et al_. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in

human breast cancer. _Virchows Archiv A_ 1986; 409: 127–147. Article  CAS  Google Scholar  * Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q _et al_. An online survival

analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. _Breast Cancer Res Treat_ 2010; 123: 725–731. Article  PubMed 

CAS  Google Scholar  * Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F _et al_. Androgen receptor levels and association with PIK3CA mutations and prognosis

in breast cancer. _Clin Cancer Res_ 2009; 15: 2472–2478. Article  CAS  PubMed  Google Scholar  * Luo X, Shi YX, Li ZM, Jiang WQ . Expression and clinical significance of androgen receptor in

triple negative breast cancer. _Chin J Cancer_ 2010; 29: 585–590. Article  CAS  PubMed  Google Scholar  * Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R . Androgen receptor in

breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. _Mod Pathol_ 2010; 23: 205–212. Article  CAS  PubMed 

Google Scholar  * Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S _et al_. Androgen receptor expression in primary breast cancer and its predictive and prognostic

value in patients treated with neoadjuvant chemotherapy. _Breast Cancer Res Treat_ 2011; 130: 477–487. Article  CAS  PubMed  Google Scholar  * Tsutsumi Y . Apocrine carcinoma as

triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. _Jpn J Clin

Oncol_ 2012; 42: 375–386. Article  PubMed  Google Scholar  * Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA _et al_. Phase II trial of bicalutamide in patients with androgen

receptor-positive, estrogen receptor-negative metastatic breast cancer. _Clin Cancer Res_ 2013; 19: 5505–5512. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang Y, Romigh T, He X,

Tan MH, Orloff MS, Silverman RH _et al_. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. _Oncogene_ 2011; 30: 4327–4338. Article  CAS  PubMed

  Google Scholar  * Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P _et al_. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Iimmunohistochemical analysis

in breast cancer cell lines. _Breast Cancer (Auckl)_ 2010; 4: 35–41. PubMed Central  Google Scholar  * Wang Y, He X, Yu Q, Eng C . Androgen receptor-induced tumor suppressor, KLLN, inhibits

breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. _Hum Mol Genet_ 2013; 22: 2263–2272. Article  CAS  PubMed  Google Scholar  * Hickey TE,

Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK _et al_. Expression of androgen receptor splice variants in clinical breast cancers. _Oncotarget_ 2015; 6: 44728–44744. Article  PubMed 

PubMed Central  Google Scholar  * Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD _et al_. Identification of androgen receptor splice variant transcripts in breast cancer cell

lines and human tissues. _Horm Cancer_ 2014; 5: 61–71. Article  CAS  PubMed  Google Scholar  * Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM _et al_.

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. _Cancer Res_ 2009; 69: 6131–6140. Article  CAS  PubMed  Google Scholar  * Castellano I, Allia

E, Accortanzo V, Vandone AM, Chiusa L, Arisio R _et al_. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. _Breast Cancer Res

Treat_ 2010; 124: 607–617. Article  CAS  PubMed  Google Scholar  * Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K _et al_. Androgen receptor expression and breast cancer survival

in postmenopausal women. _Clin Cancer Res_ 2011; 17: 1867–1874. Article  CAS  PubMed  PubMed Central  Google Scholar  * Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schutze D _et al_.

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. _J Cancer Res Clin Oncol_ 2013; 139: 809–816.

Article  CAS  PubMed  Google Scholar  * Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F . Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast

cancers. _Virchows Arch_ 2010; 457: 467–476. Article  CAS  PubMed  Google Scholar  * Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS _et al_. Androgen receptor expression is significantly

associated with better outcomes in estrogen receptor-positive breast cancers. _Ann Oncol_ 2011; 22: 1755–1762. Article  CAS  PubMed  Google Scholar  * Abdulla A, Zhang Y, Hsu FN, Xiaoli AM,

Zhao X, Yang ES _et al_. Regulation of lipogenic gene expression by lysine-specific histone demethylase-1 (LSD1). _J Biol Chem_ 2014; 289: 29937–29947. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y _et al_. Targeting androgen receptor in estrogen receptor-negative breast cancer. _Cancer Cell_ 2011; 20: 119–131.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG _et al_. Androgen receptor driven transcription in molecular

apocrine breast cancer is mediated by FoxA1. _EMBO J_ 2011; 30: 3019–3027. Article  CAS  PubMed  PubMed Central  Google Scholar  * Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB,

Shyr Y _et al_. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. _J Clin Invest_ 2011; 121: 2750–2767. Article  CAS

  PubMed  PubMed Central  Google Scholar  * McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H . Androgen receptor in triple negative breast cancer. _J Steroid Biochem Mol Biol_ 2013;

133: 66–76. Article  CAS  PubMed  Google Scholar  * He J, Peng R, Yuan Z, Wang S, Peng J, Lin G _et al_. Prognostic value of androgen receptor expression in operable triple-negative breast

cancer: a retrospective analysis based on a tissue microarray. _Med Oncol_ 2012; 29: 406–410. Article  CAS  PubMed  Google Scholar  * Tang D, Xu S, Zhang Q, Zhao W . The expression and

clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. _Med Oncol_ 2012; 29: 526–533. Article  CAS  PubMed  Google Scholar  * Mrklic I, Pogorelic Z,

Capkun V, Tomic S . Expression of androgen receptors in triple negative breast carcinomas. _Acta Histochem_ 2013; 115: 344–348. Article  CAS  PubMed  Google Scholar  * Rakha EA, El-Sayed ME,

Green AR, Lee AH, Robertson JF, Ellis IO . Prognostic markers in triple-negative breast cancer. _Cancer_ 2007; 109: 25–32. Article  CAS  PubMed  Google Scholar  * Harwood DT, Handelsman DJ

. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. _Clin Chim

Acta_ 2009; 409: 78–84. Article  CAS  PubMed  Google Scholar  * Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P _et al_. Reexamination of testosterone, dihydrotestosterone,

estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. _Steroids_ 2011; 76: 177–182. Article  CAS 

PubMed  Google Scholar  * Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC . Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with

an ID-LC-MS/MS method and a 2nd generation automated immunoassay. _Steroids_ 2013; 78: 96–101. Article  CAS  PubMed  Google Scholar  * Amente S, Lania L, Majello B . The histone LSD1

demethylase in stemness and cancer transcription programs. _Biochim Biophys Acta_ 2013; 1829: 981–986. Article  CAS  PubMed  Google Scholar  * Shi Y, Lan F, Matson C, Mulligan P, Whetstine

JR, Cole PA _et al_. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. _Cell_ 2004; 119: 941–953. Article  CAS  PubMed  Google Scholar  * Wissmann M, Yin N, Muller

JM, Greschik H, Fodor BD, Jenuwein T _et al_. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. _Nat Cell Biol_ 2007; 9: 347–353. Article 

CAS  PubMed  Google Scholar  * Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A _et al_. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene

expression. _Science_ 2008; 319: 202–206. Article  CAS  PubMed  Google Scholar  * Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS _et al_. Histone

methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. _Cell_ 2007; 128: 505–518. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nair

SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schule R _et al_. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating

lysine demethylase 1 specificity. _EMBO Rep_ 2010; 11: 438–444. Article  CAS  PubMed  PubMed Central  Google Scholar  * Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B .

LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. _Oncogene_ 2010; 29: 3691–3702. Article  CAS  PubMed  Google Scholar  * Amente S, Lania L, Avvedimento

EV, Majello B . DNA oxidation drives Myc mediated transcription. _Cell Cycle_ 2010; 9: 3002–3004. Article  CAS  PubMed  Google Scholar  * Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia

T, Wassell R _et al_. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. _Mol Cell_ 2002; 10: 1119–1128. Article  CAS 

PubMed  Google Scholar  * Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KS, Allis CD _et al_. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through

distinct partner protein complexes. _Proc Natl Acad Sci USA_ 2011; 108: 15751–15756. Article  CAS  PubMed  PubMed Central  Google Scholar  * Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK,

Teng CM _et al_. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. _Mol Pharmacol_ 2011;

79: 197–206. Article  CAS  PubMed  PubMed Central  Google Scholar  * Feng J, Xu G, Liu J, Zhang N, Li L, Ji J _et al_. Phosphorylation of LSD1 at Ser112 is crucial for its function in

induction of EMT and metastasis in breast cancer. _Breast Cancer Res Treat_ 2016; 159: 443–456. Article  CAS  PubMed  Google Scholar  * Verrijdt G, Haelens A, Claessens F . Selective DNA

recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. _Mol Genet Metab_ 2003; 78: 175–185. Article  CAS  PubMed  Google Scholar  * Nelson

JD, Denisenko O, Bomsztyk K . Protocol for the fast chromatin immunoprecipitation (ChIP) method. _Nat Protoc_ 2006; 1: 179–185. Article  CAS  PubMed  Google Scholar  * Harmeyer KM, South PF,

Bishop B, Ogas J, Briggs SD . Immediate chromatin immunoprecipitation and on-bead quantitative PCR analysis: a versatile and rapid ChIP procedure. _Nucleic Acids Res_ 2015; 43: e38. Article

  PubMed  CAS  Google Scholar  * Kocatürk B, Versteeg HH . Orthotopic injection of breast cancer cells into the mammary fat pad of mice to study tumor growth. _J Vis Exp_ 2015; e-pub ahead

of print 8 February 2015doi:10.3791/51967. Download references ACKNOWLEDGEMENTS We thank Dr Wei Huang from School of Mathematics and Statistics of Northeast Normal University for kindly

providing statistical analysis guidance. This work was supported by the grants from the National Natural Science Foundation of China (Grant numbers 31570718, 31571478, 31571317 and

31371294), and a grant from The University S & T Innovation Platform of Jilin Province for Economic Fungi (#2014B-1). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * The Key Laboratory of

Molecular Epigenetics of Ministry of Education (MOE), Northeast Normal University, Changchun, China J Feng, L Li, J Liu, Y Zhang & B Huang * Department of Bone and Soft Tissue Tumors,

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China L Li * The Institute

of Genetics and Cytology, Northeast Normal University, Changchun, China N Zhang, X Li & J Lu * Department of Pathology, The Second Hospital of Jilin University, Changchun, China L Zhang 

& H Gao * National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun, China G Wang & Y Li * School of Science, Auckland

University of Technology, Auckland, New Zealand D Liu Authors * J Feng View author publications You can also search for this author inPubMed Google Scholar * L Li View author publications

You can also search for this author inPubMed Google Scholar * N Zhang View author publications You can also search for this author inPubMed Google Scholar * J Liu View author publications

You can also search for this author inPubMed Google Scholar * L Zhang View author publications You can also search for this author inPubMed Google Scholar * H Gao View author publications

You can also search for this author inPubMed Google Scholar * G Wang View author publications You can also search for this author inPubMed Google Scholar * Y Li View author publications You

can also search for this author inPubMed Google Scholar * Y Zhang View author publications You can also search for this author inPubMed Google Scholar * X Li View author publications You can

also search for this author inPubMed Google Scholar * D Liu View author publications You can also search for this author inPubMed Google Scholar * J Lu View author publications You can also

search for this author inPubMed Google Scholar * B Huang View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHORS Correspondence to J Lu or

B Huang. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION Supplementary Information accompanies this paper on the Oncogene website

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATIONS (DOCX 46 KB) SUPPLEMENTARY FIGURES (DOCX 17 KB) SUPPLEMENTARY TABLE 1 (DOCX 23 KB) SUPPLEMENTARY TABLE 2 (DOCX 22 KB) SUPPLEMENTARY

TABLE 3 (DOCX 24 KB) SUPPLEMENTARY FIGURE 1 (JPG 1099 KB) SUPPLEMENTARY FIGURE 2 (JPG 1596 KB) SUPPLEMENTARY FIGURE 3 (JPG 1109 KB) SUPPLEMENTARY FIGURE 4 (JPG 632 KB) SUPPLEMENTARY FIGURE 5

(JPG 1007 KB) SUPPLEMENTARY FIGURE 6 (JPG 2809 KB) SUPPLEMENTARY FIGURE 7 (JPG 3852 KB) SUPPLEMENTARY FIGURE 8 (JPG 1816 KB) SUPPLEMENTARY FIGURE 9 (JPG 7556 KB) RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Feng, J., Li, L., Zhang, N. _et al._ Androgen and AR contribute to breast cancer development and metastasis: an insight of

mechanisms. _Oncogene_ 36, 2775–2790 (2017). https://doi.org/10.1038/onc.2016.432 Download citation * Received: 23 May 2016 * Revised: 08 October 2016 * Accepted: 19 October 2016 *

Published: 28 November 2016 * Issue Date: 18 May 2017 * DOI: https://doi.org/10.1038/onc.2016.432 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative